WHWK - Wutah bathi EPS kuartalan Aadi Bioscience

The current quarterly EPS rate demonstrates yield dynamics, where 12.10 reflects the latest metric value. Aadi Bioscience Inc (WHWK) is building a precision oncology ecosystem by linking clinics through exclusive supplies of the drug Fyarro. A team of elite scientists is retained by the prestige of working with mTOR inhibitors. The autonomous commercialization cycle of targeted therapy protects the company's revenue from global economic downturns.

Sales of the drug Fyarro form the foundation of Aadi Bioscience Inc (WHWK) cash flow, determining the company's ability to generate real profit. This trend is reflected in the calculation of the percentage change in quarterly net income per share, which allows the current quarterly EPS growth rate to separate fundamental growth from market volatility and assess the risk of overpaying for the asset.